在有心脏病或肾脏风险的糖尿病患者中,口服硫酸盐将重大心脏病事件减少14%。 Oral semaglutide reduces major heart events by 14% in diabetes patients with heart or kidney risks.

据最近的一项研究显示,口服的糖尿病药物西马格卢提德可在2型糖尿病患者和心血管或脏问题患者中减少14%的严重心脏事件. Oral semaglutide, a diabetes medication taken by mouth, reduced major heart events by 14% in patients with type 2 diabetes and cardiovascular or kidney issues, according to a recent study. 这项涉及近10 000名病人的试验发现,非致命心脏病发作和中风显著减少。 The trial, involving nearly 10,000 patients, found significant decreases in nonfatal heart attacks and strokes. 这种口头形式可以提供一种非注射的替代办法,扩大高风险病人的治疗选择。 This oral form could offer a non-injection alternative, expanding treatment options for high-risk patients.